Metropolis Healthcare Limited (NSE:METROPOLIS)
India · Delayed Price · Currency is INR | Market Cap | 113.62B +25.4% |
| Revenue (ttm) | 15.66B +18.9% |
| Net Income | 1.68B +10.5% |
| EPS | 8.10 +9.5% |
| Shares Out | 207.33M |
| PE Ratio | 67.67 |
| Forward PE | 44.90 |
| Dividend | 1.00 (0.18%) |
| Ex-Dividend Date | n/a |
| Volume | 301,485 |
| Average Volume | 683,048 |
| Open | 549.00 |
| Previous Close | 548.10 |
| Day's Range | 541.30 - 559.10 |
| 52-Week Range | 397.08 - 574.90 |
| Beta | 0.14 |
| RSI | 73.49 |
| Earnings Date | May 13, 2026 |
About Metropolis Healthcare
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provid... [Read more]
Financial Performance
In fiscal year 2025, Metropolis Healthcare's revenue was 13.31 billion, an increase of 10.23% compared to the previous year's 12.08 billion. Earnings were 1.45 billion, an increase of 13.42%.
Financial StatementsNews
Metropolis Healthcare Ltd (BOM:542650) Q3 2026 Earnings Call Highlights: Robust Revenue Growth ...
Metropolis Healthcare Ltd (BOM:542650) Q3 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions
Q3 2026 Metropolis Healthcare Ltd Earnings Call Transcript
Q3 2026 Metropolis Healthcare Ltd Earnings Call Transcript
Metropolis Healthcare Transcript: Q3 25/26
Q3 saw 26% group revenue growth and 29% organic EBITDA growth year-on-year, with strong performance across B2C and B2B segments and expanding margins. Strategic focus on genomics, digital, and network expansion continues, while a 3:1 bonus share issue was announced.
Metropolis Healthcare Ltd (BOM:542650) Q3 2026: Everything You Need To Know Ahead Of Earnings
Metropolis Healthcare Ltd (BOM:542650) Q3 2026: Everything You Need To Know Ahead Of Earnings
Metropolis Healthcare launches Centre of Genomics to scale precision diagnostics in India
Metropolis Healthcare Limited on Tuesday announced the launch of its Centre of Genomics, marking a strategic expansion of its advanced...
Metropolis Healthcare shares rise over 3% after strong Q3 FY26 business update
Shares of Metropolis Healthcare traded higher in Monday’s session after the diagnostics company reported a strong business performance for the...
Metropolis Healthcare reports 26% revenue growth in Q3 FY26; wellness and specialty segments drive demand
Metropolis Healthcare Limited has reported a strong operating performance in the December quarter of FY26, with consolidated revenue rising around...
Metropolis Healthcare Ltd (BOM:542650) Q2 2026 Earnings Call Highlights: Strong Revenue Growth ...
Metropolis Healthcare Ltd (BOM:542650) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Margin Expansion
Q2 2026 Metropolis Healthcare Ltd Earnings Call Transcript
Q2 2026 Metropolis Healthcare Ltd Earnings Call Transcript
Metropolis Healthcare Transcript: Q2 25/26
Group revenue grew 23% year-over-year with strong organic margin expansion and double-digit volume growth. Integration of recent acquisitions is progressing, and guidance for margin and top-line growth is maintained for FY2026.
Metropolis Healthcare shares jump over 3% as Q2 revenue rises 22.7% YoY to Rs 429 crore, net profit up 13.2%
Metropolis Healthcare shares jumped more than 3% in early trade after the diagnostics company reported a strong set of earnings...
What To Expect From Metropolis Healthcare Ltd (BOM:542650) Q2 2026 Earnings
What To Expect From Metropolis Healthcare Ltd (BOM:542650) Q2 2026 Earnings
Metropolis Healthcare incorporates new subsidiary Metropolis Quality Solutions
Metropolis Healthcare Limited on Tuesday announced the incorporation of a new wholly owned subsidiary, Metropolis Quality Solutions Private Limited, effective September 15, 2025. The newly incorporate...
Metropolis Healthcare shares jump nearly 3% following Q1 results; Company projects over 12% revenue growth in FY26
Shares of Metropolis Healthcare Ltd surged 2.86% to ₹2,065.90 on Monday, adding ₹57.50 in early trade. The stock, listed on NSE, has a market capitalisation of ₹10,513.48 crore and has traded between ...
Metropolis Healthcare Transcript: Q1 25/26
Q1 FY2026 saw 23% group revenue growth and 13.2% organic growth, with margin expansion and strong performance in specialty and preventive diagnostics. Integration of recent acquisitions is on track, and further growth is expected in Tier 2/3 markets and B2C share.
Metropolis Healthcare eyes double-digit growth as B2C gains traction
Nuvama Institutional Equities has reiterated a ‘Buy’ rating on Metropolis Healthcare, maintaining its target price at ₹2,240 per share. The brokerage cited improving business mix, strong B2C performan...
Metropolis Healthcare shares rise over 2% today as specialty and TruHealth segments post strong Q1 growth
On Monday, 7th July, shares of Metropolis Healthcare Ltd gained 2.35% to ₹1,815 on the NSE, rising ₹41.70 from the previous close of ₹1,773.30. The stock moved higher after the company shared its busi...
Dr Lal PathLabs, Metropolis Healthcare shares decline as Amazon Diagnostics enters market
Shares of diagnostic service providers Dr Lal PathLabs and Metropolis Healthcare slipped in Monday’s trade following Amazon India’s announcement of its foray into the diagnostics space. Amazon launche...
Metropolis Healthcare Transcript: Q4 24/25
FY25 saw 12% revenue growth, strong B2C momentum, and three strategic acquisitions to boost North India presence. FY26 guidance is for 25-26% total revenue growth, 100 bps organic margin expansion, and continued focus on operational efficiency and digital transformation.
Metropolis Healthcare to acquire Dr. Ahujas’ Pathology & Imaging Centre for Rs 35 crore
Metropolis Healthcare Limited, India’s second-largest pathology laboratory chain, has announced a strategic acquisition to bolster its foothold in North India. The company’s wholly owned subsidiary, M...
Metropolis Healthcare posts 10% YoY revenue growth in Q4 FY25, wellness segment drives performance
Metropolis Healthcare Limited reported a 10% year-on-year revenue growth for the fourth quarter of FY25, despite facing challenges in the acute testing and specialty segments. The company, which opera...
Stocks hitting 52-week low today, April 1: Titan Company, Tata Elxsi, UCO Bank, Birlasoft, Metropolis Healthcare and more
The Indian stock market experienced a significant downturn on April 1, as both major indices, Sensex and Nifty, closed in the red for the second consecutive session. The Sensex plunged by 1,390.41 poi...
Metropolis Healthcare to acquire scientific pathology’s business in Agra for up to Rs 83 Crore
Metropolis Healthcare Limited has announced the acquisition of the business operations of Dr. Ashok Kumar Sharma’s Scientific Pathology, a diagnostic service provider in Agra and neighboring towns. Th...
Metropolis Health shares jump 3% as revenue rises 11% YoY in Q3
Metropolis Health shares jumped more than 3% in morning trade after the company announced its solid Q3 results. As of 10:09 AM, the shares were trading 2.85% higher at Rs 1,787.45. The company posted ...
Metropolis Healthcare Transcript: Q3 24/25
Q3 FY25 saw 11% revenue growth, with B2C now 55% of revenue and strong gains in wellness and specialty testing. The Core Diagnostics acquisition is set to close soon, expected to be EPS accretive from year one, with margin normalization in 2-3 years. Margin guidance remains at 25%+ for Q4 and beyond.